NAVIDEA BIOPHARMACEUTICALS I's ticker is NAVB and the CUSIP is 63937X202. A total of 40 filers reported holding NAVIDEA BIOPHARMACEUTICALS I in Q3 2020. The put-call ratio across all filers is 0.51 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $24,801 | -2.5% | 276,491 | 0.0% | 0.00% | – |
Q2 2023 | $25,437 | -65.9% | 276,491 | -3.5% | 0.00% | – |
Q1 2023 | $74,526 | -46.9% | 286,638 | -57.1% | 0.00% | – |
Q4 2022 | $140,226 | -22.5% | 667,740 | -6.4% | 0.00% | – |
Q3 2022 | $181,000 | -65.8% | 713,129 | -3.2% | 0.00% | – |
Q2 2022 | $530,000 | -8.9% | 736,923 | 0.0% | 0.00% | – |
Q1 2022 | $582,000 | -21.0% | 736,923 | 0.0% | 0.00% | – |
Q4 2021 | $737,000 | -43.0% | 736,923 | -0.2% | 0.00% | – |
Q3 2021 | $1,292,000 | -3.2% | 738,361 | +1.2% | 0.00% | – |
Q2 2021 | $1,335,000 | -9.4% | 729,761 | 0.0% | 0.00% | – |
Q1 2021 | $1,474,000 | -6.1% | 729,761 | 0.0% | 0.00% | – |
Q4 2020 | $1,569,000 | -21.8% | 729,761 | -1.8% | 0.00% | – |
Q3 2020 | $2,006,000 | +24.1% | 743,059 | +81.0% | 0.00% | – |
Q2 2020 | $1,617,000 | +430.2% | 410,510 | +2.6% | 0.00% | – |
Q1 2020 | $305,000 | +17.3% | 400,078 | +93.8% | 0.00% | – |
Q4 2019 | $260,000 | +81.8% | 206,434 | 0.0% | 0.00% | – |
Q3 2019 | $143,000 | +25.4% | 206,434 | +14.7% | 0.00% | – |
Q2 2019 | $114,000 | – | 179,985 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Allred Capital Management, LLC | 52,926 | $113,000 | 0.06% |
BRIDGEWAY CAPITAL MANAGEMENT, LLC | 109,940 | $236,000 | 0.01% |
PATHSTONE FAMILY OFFICE, LLC | 10,050 | $22,000 | 0.00% |
Sowell Financial Services LLC | 11,190 | $24,000 | 0.00% |
TWO SIGMA INVESTMENTS, LP | 101,949 | $219,000 | 0.00% |
SUSQUEHANNA FUNDAMENTAL INVESTMENTS, LLC | 32,822 | $71,000 | 0.00% |
UBS Group AG | 816 | $2,000 | 0.00% |
IFP Advisors, Inc | 50 | $0 | 0.00% |
OSAIC HOLDINGS, INC. | 6 | $0 | 0.00% |
Jacobi Capital Management LLC | 1,000 | $2,000 | 0.00% |